Illumina, Inc.: Argus Research Elevates Price Target to $180 Amidst Robust Genomic Sector Growth and Strategic Advancements
Argus Research, a respected independent investment research firm, has announced an upgrade to its price target for Illumina, Inc. (NASDAQ: ILMN) shares, raising it to $180. The revised outlook, issued…
